Edwards’ device, dubbed Sapien M3, is the first approved system to use a transfemoral approach to treating mitral ...

Edwards Lifesciences Corporation today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic ...

Career Achievement Award will be presented to Stephan Windecker, MD, during Transcatheter Cardiovascular Therapeutics® (TCT®) ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

joint frailty model hazard ratio 0.72, one-sided upper confidence limit of 0.93, p=0.02). Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years ...

Tricuspid valve surgery exhibited the highest cumulative incidence ... Competing risks regression was performed using the Fine-Gray proportional subdistribution hazards model in which all-cause ...

Conclusion Most patients in a specialist murmur clinic had normal auscultation and point-of-care scans and no additional valve disease was detected by standard echocardiography. This suggests that a ...